ArticleAIDS (London, England)2026
Longitudinal challenges faced by perinatally-infected young people with HIV in Kenya during the COVID-19 pandemic.
Article in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundUnderstanding challenges experienced by adolescents and youth with HIV (AYWH) during COVID-19 can inform care during health crises.
methodsFrom 2021 to 2023, bi-monthly in-person/phone surveys were administered to assess trends in psychological, physical, and socioeconomic challenges, and antiretroviral nonadherence, among Kenyan AYWH, alongside COVID-19 burden [caseloads and Oxford-Stringency-Index (OSI)]. Biannual viral loads (VLs) were described as virologic suppression (VL ≤ 40 copies/ml), virologic failure (VL > 40 copies/ml), and treatment failure (VL > 1000 copies/ml). Associations among caseloads/OSI, challenges, nonadherence, and treatment failure transitions (VL ≤ 1000 to >1000 copies/ml and vice versa) were evaluated using regression models, accounting for repeated-measures, age, gender, clinic, and between-visit days.
resultsAmong 441 participants (mean age 16.9 years, 49% female, mean time on antiretroviral therapy (ART) 11.9 years), 89% reported at enrollment challenges (48% psychological, 66% physical, 61% socioeconomic). Within-subject challenges, COVID-19 caseloads, and OSI scores varied over time alongside pandemic changes. During stringent periods and surges, physical challenges worsened [odds ratio (OR) = 1.04 per 100-cases increase/day, 95% confidence interval (CI) = 1.00-1.08]; psychological challenges were stable (OR = 1.02, CI = 0.98-1.06); socioeconomic challenges worsened during caseloads upticks (OR = 2.08, CI = 1.14-3.81). Higher challenges burden at enrollment was associated with slower reduction in challenges over time. Nonadherence (74% at enrollment) was associated with higher prior-visit challenges (psychological: OR = 1.37, CI = 1.24-1.51; physical: OR = 1.43, CI = 1.22-1.69; socioeconomic: OR = 1.27, CI = 1.11-1.46). Virologic and treatment failure occurred in 19% and 10%; suppression-to-failure transition was associated with worsening adherence (OR = 1.26, CI = 1.00-1.58).
conclusionsKenyan AYWH experienced substantial wellness challenges during COVID-19, possibly prompting poor adherence and viral outcomes. While stability of nonphysical challenges suggests COVID-19 adaptation, targeted interventions are warranted to support this vulnerable population during public health crises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.